Top Industry Leaders in the Vasomotor Symptoms Market
Astellas' VEOZATM Received EU approval in December 2023 and US FDA approval in May 2023 for treating moderate to severe VMS due to menopause.First non-hormonal neurokinin 3 (NK3) receptor antagonist approved for VMS, offering a new option for women seeking non-hormonal treatment.
Abbott's Upledity Launched in the US in November 2023 for moderate to severe VMS and other menopausal symptoms. Offers a new low-dose oral hormonal option for some women.
Therapeutics Unlimited's Zyla Received FDA approval in November 2023 for the treatment of menopausal symptoms, including VMS. Offers a new topical estrogen option for women seeking to avoid systemic treatments.
List of Vasomotor Symptoms Key companies in the market- Allergan (Ireland)
- Pfizer Inc. (US)
- Eli Lily and Company (US)
- Novartis AG (Switzerland)
- Emcure Pharmaceuticals Ltd (India)
- Merck & Co.Inc. (US)
- TherapeuticsMD Inc. (US)
- Mithra Pharmaceuticals (Belgium)